Effects of Mass Drug Administration of Azithromycin on Mortality and Other Outcomes Among 1-11 Month Old Infants in Mali

PHASE3CompletedINTERVENTIONAL
Enrollment

149,201

Participants

Timeline

Start Date

October 15, 2020

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2024

Conditions
Mortality
Interventions
DRUG

Placebo

Placebo mixture will be administered as a single dose in oral suspension form for children 1-11 months of age. Weight-based dosing will be used: single-dose of 0.5 ml / kg child weight.

DRUG

Azithromycin

Azithromycin will be administered as a single dose in oral suspension form for children 1-11 months of age. Weight-based dosing will be used: single-dose of 0.5 ml (20 mg) / kg child weight.

Trial Locations (1)

BP 251

Center for Vaccine Development CVD-Mali, Bamako

All Listed Sponsors
collaborator

Center for Vaccine Development CVD-Mali, Bamako, Mali

UNKNOWN

collaborator

University College London Hospitals

OTHER

collaborator

Tro Da Ltd, UK

UNKNOWN

collaborator

Duke-NUS Graduate Medical School

OTHER

collaborator

Bill and Melinda Gates Foundation

OTHER

collaborator

Pfizer Inc. (Provider of study drugs)

UNKNOWN

lead

Tampere University

OTHER

NCT04424511 - Effects of Mass Drug Administration of Azithromycin on Mortality and Other Outcomes Among 1-11 Month Old Infants in Mali | Biotech Hunter | Biotech Hunter